TY - JOUR
T1 - Correlation of PD-L1 immunohistochemical expression with microsatellite instability and p53 status in endometrial carcinoma; endometrial carcinoma tissue markers
AU - Arafa, Mohammad
AU - Shebl, Abdelhadi Mohamed
AU - Salama, Amany
AU - ElZahaf, Eman
AU - Ashamallah, Sylvia A
AU - Foda, Abd AlRahman
AU - Awad, AzmyAbd El-Hameed
AU - Shalaby, Asem
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/12
Y1 - 2022/12
N2 - BACKGROUND: Endometrial carcinoma (EC) is the most common gynaecological cancer worldwide. The Cancer Genome Atlas molecular grouping of a given case of EC could be assessed by POLE gene mutation, mismatch repair (MMR) 'to reflect microsatellite instability' and p53 status, which has proved to be of prognostic value. Programmed cell death receptor 1 (PD-1) and its ligand (PD-L1) are playing a progressively important role in tumour immunology and cancer treatment.OBJECTIVES: To investigate PD-L1 immunohistochemical expression in EC in relation to MMR and p53 status. Associations between marker expression and different histopathological parameters were also investigated.METHODS: This retrospective study was performed on archival biopsies of 170 cases of EC using a tissue microarray model. Immunohistochemical staining was applied using antibodies against PD-L1, MLH1, MSH2 and p53.RESULTS: The percentages of positivity were as follows: PD-L1, 19.6%; MLH1, 79.5%; MSH2, 78.5%; and p53 mutant, 13.8%. There was significant correlation between MLH1 expression and MSH2 expression (p = 0.008). Tumour grade was significantly correlated with stage (p = 0.005) and p53 mutant expression (p = 0.008). Combined PD-L1 positivity and MMR deficiency showed significant correlation with the presence of lymphovascular space invasion (p = 0.014). MSH2 negativity was significantly associated with poorer overall survival (p = 0.014).CONCLUSIONS: A panel of immunohistochemical markers (PD-L1, MLH1, MSH2 and p53) could help to predict the prognosis and plan the treatment of patients with EC. MMR deficiency seems to be a good predictor for PD-L1 status, and therefore the response to potential PD-1/PD-L1 inhibitor therapy.
AB - BACKGROUND: Endometrial carcinoma (EC) is the most common gynaecological cancer worldwide. The Cancer Genome Atlas molecular grouping of a given case of EC could be assessed by POLE gene mutation, mismatch repair (MMR) 'to reflect microsatellite instability' and p53 status, which has proved to be of prognostic value. Programmed cell death receptor 1 (PD-1) and its ligand (PD-L1) are playing a progressively important role in tumour immunology and cancer treatment.OBJECTIVES: To investigate PD-L1 immunohistochemical expression in EC in relation to MMR and p53 status. Associations between marker expression and different histopathological parameters were also investigated.METHODS: This retrospective study was performed on archival biopsies of 170 cases of EC using a tissue microarray model. Immunohistochemical staining was applied using antibodies against PD-L1, MLH1, MSH2 and p53.RESULTS: The percentages of positivity were as follows: PD-L1, 19.6%; MLH1, 79.5%; MSH2, 78.5%; and p53 mutant, 13.8%. There was significant correlation between MLH1 expression and MSH2 expression (p = 0.008). Tumour grade was significantly correlated with stage (p = 0.005) and p53 mutant expression (p = 0.008). Combined PD-L1 positivity and MMR deficiency showed significant correlation with the presence of lymphovascular space invasion (p = 0.014). MSH2 negativity was significantly associated with poorer overall survival (p = 0.014).CONCLUSIONS: A panel of immunohistochemical markers (PD-L1, MLH1, MSH2 and p53) could help to predict the prognosis and plan the treatment of patients with EC. MMR deficiency seems to be a good predictor for PD-L1 status, and therefore the response to potential PD-1/PD-L1 inhibitor therapy.
KW - Endometrial carcinoma
KW - Immunotherapy
KW - MMR
KW - P53
KW - PD-L1
KW - Prognostic markers
UR - http://www.scopus.com/inward/record.url?scp=85142310524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142310524&partnerID=8YFLogxK
U2 - 10.1016/j.eurox.2022.100172
DO - 10.1016/j.eurox.2022.100172
M3 - Article
C2 - 36440057
SN - 2590-1613
VL - 16
SP - 100172
JO - European Journal of Obstetrics and Gynecology and Reproductive Biology: X
JF - European Journal of Obstetrics and Gynecology and Reproductive Biology: X
M1 - 100172
ER -